BioBoomer

Entrepreneur, Investor

[BioBoomer @BioBoomer]

$GERN They can use the drug for multiple indications thru drug titration and clinical trails. This will be a $50 drug competing with big pharma someday.

[Investor News @newsfilterio]

Form SC 13G/A (statement of acquisition of beneficial ownership by individuals) filed with the SEC $GERN https://t.co/DWMYOyQ8pT

[BioBoomer @BioBoomer]

@iamSeanSahand It's around $3. What do you say now? You can't value a cancer drug company so low. It takes more than a billion dollars to pull one drug, $CLVS will be valued atleast at between $3-$10 Billion for it's assets unless #mahaffey fucks it up.

[BioBoomer @BioBoomer]

$CLVS tailwinds from excellent clinical data. More to come in the pipeline with #Rubraca already approved by #FDA. Looks promising for a BuyOut. This stock has been to $60+ twice. This time it may stay there until BO. Build generational wealth and fight cancer. $SPY $AMC $GME

[BioBoomer @BioBoomer]

#FDA is now accepting #RWE data to approve additional indications on approved drugs which is going to be cheap, reliable and fast. #21stcenturycaresact

[BioBoomer @BioBoomer]

$CLVS This is just a begining. If you know anything about #Oncology drugs, these types of products have the ability to file for multiple indications based on the pathway. I can see this being a multi-billion $ opportunity.

[Bloomberg Markets @markets]

China said its giant Sky Eye telescope may have picked up signs of life beyond Earth, according to a report by state-backed publication that then appeared to have deleted it and other posts https://t.co/bKoNw4tZns

[BioBoomer @BioBoomer]

$CLVS Wait for 2 more catalysts. This is a $20 stock for 2022

[Alex Vindman 🇺🇸 @AVindman]

Fascinating thread. Must be read to the end.

[BioBoomer @BioBoomer]

$ACRX https://t.co/GIZZ1VcTsS

[BioBoomer @BioBoomer]

@_Zenil_ Another coincidence, paulchoi loves $5 shorts. Try #oldnavy not $CLVS

[BioBoomer @BioBoomer]

@MarketCurrents "disproportionate for data that was already disclosed". Funny! @GoldmanSachs needs education on #clinicaltrials process. Someone lost a lot of money on the short and timing of this article being Friday is suspect. Guessing the strike price was $5. Hope he finds his next job soon

[BioBoomer @BioBoomer]

$CLVS ripping higher. #buyout chances could push it into $20+

[stock setter @MarcJacksonLA]

$SRPT Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 https://t.co/JUewESk8Cn

[BioBoomer @BioBoomer]

I am sending you 1π! Pi is a new digital currency developed by Stanford PhDs, with over 10 million members worldwide. To claim your Pi, follow this link https://t.co/ySsgJg58qW and use my username (piemeup) as your invitation code.

[Sun g @sunrgu]

@bio_clouseau They should just acquire $CLVS which is cheap and know where drug can work. With their sales muscle power they can generate ROI very quickly.

[BioBoomer @BioBoomer]

$clvs good to a stock like this go up. Well deserving. Expect $25+ for true value of this stonk

[BioBoomer @BioBoomer]

@saxena_puru Any opinion on $UVXY in the short term?

[BioBoomer @BioBoomer]

$SRNE Saliva test was not the reason this company is in the spotlight. It's the Antibodies they are developing. #BTFD

[BioBoomer @BioBoomer]

@CNNBusiness Isn't this close to maintaining modern day slavery by widening income inequality? Billions are being poured into rich folks coffeurs whereas the needy are made to work and risk lives. #Autocracy